These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 39041209)
1. Progastrin-Releasing Peptide As a Diagnostic Biomarker of Pulmonary and Non-Pulmonary Neuroendocrine Neoplasms. La Salvia A; Fanciulli G Endocr Res; 2024; 49(4):243-250. PubMed ID: 39041209 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors. Tutar N; Yetkin NA; Yazıcı C; Önal Ö; Kontaş O; Keleştemur F Turk J Med Sci; 2019 Jun; 49(3):774-781. PubMed ID: 31091854 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China. Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations. Kudo K; Ohyanagi F; Horiike A; Miyauchi E; Yanagitani N; Hoshi R; Satoh Y; Motoi N; Hamanaka W; Ishikawa Y; Mun M; Sakao Y; Okumura S; Nakagawa K; Horai T; Nishio M Lung Cancer; 2011 Dec; 74(3):401-4. PubMed ID: 21529988 [TBL] [Abstract][Full Text] [Related]
5. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma. Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959 [TBL] [Abstract][Full Text] [Related]
6. Utility of the serum ProGRP level for follow-up of pulmonary carcinoid tumors. Taira N; Kawabata T; Ichi T; Kushi K; Yohena T; Kawasaki H; Ishikawa K; Kato S Am J Case Rep; 2014 Aug; 15():337-9. PubMed ID: 25109370 [TBL] [Abstract][Full Text] [Related]
7. ProGRP: a new biomarker for small cell lung cancer. Molina R; Filella X; Augé JM Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231 [TBL] [Abstract][Full Text] [Related]
8. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms. Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665 [TBL] [Abstract][Full Text] [Related]
9. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis. Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019 [TBL] [Abstract][Full Text] [Related]
10. Determining ProGRP and isoforms in lung and thyroid cancer patient samples: comparing an MS method with a routine clinical immunoassay. Torsetnes SB; Broughton MN; Paus E; Halvorsen TG; Reubsaet L Anal Bioanal Chem; 2014 Apr; 406(11):2733-8. PubMed ID: 24518900 [TBL] [Abstract][Full Text] [Related]
11. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. Uchida K; Kojima A; Morokawa N; Tanabe O; Anzai C; Kawakami M; Eto Y; Yoshimura K J Cancer Res Clin Oncol; 2002 Dec; 128(12):633-40. PubMed ID: 12474049 [TBL] [Abstract][Full Text] [Related]
12. Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma. Giovanella L; Fontana M; Keller F; Campenni' A; Ceriani L; Paone G Clin Chem Lab Med; 2021 Aug; 59(9):1569-1573. PubMed ID: 33860650 [TBL] [Abstract][Full Text] [Related]
15. An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival. Korse CM; Taal BG; Bonfrer JMG; Vincent A; van Velthuysen ML; Baas P Ann Oncol; 2011 Dec; 22(12):2625-2630. PubMed ID: 21415235 [TBL] [Abstract][Full Text] [Related]
16. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics. Bubanović G; Pavićević R; Franjević A Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223 [TBL] [Abstract][Full Text] [Related]
17. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer. Kim HR; Oh IJ; Shin MG; Park JS; Choi HJ; Ban HJ; Kim KS; Kim YC; Shin JH; Ryang DW; Suh SP J Korean Med Sci; 2011 May; 26(5):625-30. PubMed ID: 21532852 [TBL] [Abstract][Full Text] [Related]
18. A case of ectopic ACTH syndrome due to DDAVP-sensitive but V1b receptor-negative bronchial typical carcinoid with lymphatic metastasis and plasma ProGRP elevation. Yamamuro T; Inoue K; Nagai Y; Azuma D; Yamamoto A; Hara K; Kohara M; Iwata T; Nakatsuka S; Morii E; Yamamoto T Endocr J; 2018 Dec; 65(12):1161-1169. PubMed ID: 30232300 [TBL] [Abstract][Full Text] [Related]
19. Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. Korse CM; Holdenrieder S; Zhi XY; Zhang X; Qiu L; Geistanger A; Lisy MR; Wehnl B; van den Broek D; Escudero JM; Standop J; Hu M; Molina R Clin Chim Acta; 2015 Jan; 438():388-95. PubMed ID: 25262909 [TBL] [Abstract][Full Text] [Related]
20. Demonstration and diagnostic significance of pro-gastrin-releasing peptide in medullary thyroid carcinoma. Inaji H; Komoike Y; Motomura K; Higashiyama M; Ohtsuru M; Funai H; Kasugai T; Koyama H Oncology; 2000 Aug; 59(2):122-5. PubMed ID: 10971170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]